Data assessing Novo Nordisk’s investigational diabetes and obesity medication were presented at The Menopause Society's 2026 Annual Meeting.
News|Articles|May 5, 2026
GLP-1s Made Up Eight Of Every 100 Prescriptions Filled in March 2026
Author(s)Ashley Gallagher, MA
GLP-1 prescriptions surge to nearly 8% of fills, fueled by weight-loss demand.
Advertisement
Advertisement
In a shift that is redefining the landscape of modern pharmacy, nearly 8 out of every 100 prescriptions filled in March 2026 were for glucagon-like peptide-1 (GLP-1) receptor agonists. This milestone follows the largest quarter-over-quarter percentage point increase in GLP-1 RA prescribing observed since tracking began in 2019. For pharmacists on the front lines, these numbers reflect a massive acceleration in patient demand that continues to test the limits of supply chains and clinical management.
Related to this article
Eli Lilly released phase 2b trial results comparing the investigational eloralintide-tirzepatide combo with tirzepatide 15 mg alone in patients with T2D and obesity.
An abstract from the American Heart Association's Scientific Sessions 2026 reveals the continuous expansion of the GLP-1 medication class.
Type 1 and type 2 diabetes reports emphasize areas where pharmacists can act now, including CGM, cardio-kidney therapies, and equitable patient access.
Gilead’s current lenacapavir patent is what makes Dr Reddy’s Laboratories’ formulation tentative.
Mark Ey, RPh, from NCPA, joins to discuss the opportunities for independent pharmacies within the ACCESS to Pharmacy Care Program.
Researchers say this net loss is unlikely to reverse without state and federal policy changes, including PBM reform.
At the center of the debate are the growing number of manufacturer demands for claims data as a condition of 340B pricing.
Advertisement
Advertisement